Unknown

Dataset Information

0

A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis.


ABSTRACT: Recombinant vesicular stomatitis virus (VSV) is widely used as a vaccine platform. However, the capacity of VSV-based vaccines to induce mucosal immunity has not been fully investigated. In the present study, a recombinant VSV expressing coxsackievirus B3 (CVB3) major immunogen VP1 has been generated and the immune protection elicited by VSV-VP1 was evaluated. We demonstrated that intranasal delivery of VSV-VP1 can induce a potent antigen-specific mucosal immune response as well as a systemic immune response, particularly the induction of polyfunctional T cells. Importantly, mice immunized with VSV-VP1 were better protected against CVB3-induced viral myocarditis than those receiving a chitosan-formulated DNA vaccine. Increased dendritic cell (DC) maturation in the mesenteric lymph node (MLN) was observed in the mice vaccinated with VSV-VP1, which could be a potential mechanism for the protective immune response. These findings support VSV as a viral delivery vector that can induce robust mucosal immunity that should be considered for further vaccine development.

SUBMITTER: Wu F 

PROVIDER: S-EPMC7115516 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis.

Wu Fei F   Fan Xingjuan X   Yue Yan Y   Xiong Sidong S   Dong Chunsheng C  

Vaccine 20140527 31


Recombinant vesicular stomatitis virus (VSV) is widely used as a vaccine platform. However, the capacity of VSV-based vaccines to induce mucosal immunity has not been fully investigated. In the present study, a recombinant VSV expressing coxsackievirus B3 (CVB3) major immunogen VP1 has been generated and the immune protection elicited by VSV-VP1 was evaluated. We demonstrated that intranasal delivery of VSV-VP1 can induce a potent antigen-specific mucosal immune response as well as a systemic im  ...[more]

Similar Datasets

| S-EPMC5553786 | biostudies-literature
| S-EPMC3164101 | biostudies-literature
| S-EPMC3754657 | biostudies-literature
| S-EPMC5442851 | biostudies-literature
| S-EPMC5482483 | biostudies-literature
| S-EPMC4896523 | biostudies-other
| S-EPMC8590870 | biostudies-literature
| S-EPMC9067557 | biostudies-literature
| S-EPMC8310306 | biostudies-literature
| S-EPMC3235117 | biostudies-literature